Iren Medical
Misgav, IL · 1 known investors
iRen develops medical technology for dialysis patients, enabling them to continue daily activities while undergoing treatment. The company aims to reduce the burden of dialysis on quality of life for people with kidney disease.
Also known as iRen-MEDICAL · liberDi · liberDi Ltd.
Investors · 1
Company profile
researched Aug 2026iRen Medical, formerly liberDi Ltd., is an Israeli medical device company based in Misgav that develops a home peritoneal dialysis (PD) platform it calls the Digital Dialysis Clinic. The system is designed to let people on peritoneal dialysis perform treatment at home or at the workplace, and pairs patient-side hardware with remote monitoring so that providers and patients can collaborate on clinical outcomes. The company states its platform has FDA clearance, announced in January 2023.
A central component is the Intelligent Dialysis Assistant (iDA), described as an electronic automated ambulatory PD exchange device. The company emphasizes ease of use, freedom of movement, automatic catheter connection disinfection technology and patient monitoring during daily dialysis activities. iRen Medical frames the market opportunity around figures it cites, namely that one in ten people worldwide experience kidney disease or failure, that in-clinic hemodialysis is the most common treatment modality at 88% of patients, and that the 12% who use home dialysis remain confined to their homes for hours each day.
The company was founded in 2014 and operated as a portfolio company of The Trendlines Group Ltd. (SGX: 42T; OTCQX: TRNLY). Its leadership includes Hezkiah Tsoory as CEO and board member, Caroll H. Neubauer as chairman of the board, Hagai Cohen as CFO and Gideon Bregman as COO, supported by board members including Steve Rhodes, Ron Lefeber and Barak Singer, and a medical and scientific advisory group of nephrologists.
Founding story
iRen Medical was founded in 2014 as liberDi, assembling scientists, engineers, nephrology specialists and industry figures around the goal of freeing people on dialysis from spending large parts of their lives in treatment. The team based its product direction on the observation that most dialysis patients rely on in-clinic hemodialysis and that even home dialysis patients remain confined for hours daily.
Business model
iRen Medical develops and markets a home peritoneal dialysis platform combining a patient-operated device with remote clinical monitoring. The company frames the offering as a service for both patients and dialysis providers, stating that in addition to giving patients mobility, the platform enables clinics to optimize their economic model and improve service quality while lowering costs. Specific pricing, reimbursement or contracting details are not disclosed publicly.
Not disclosed in available company materials beyond the statement that the platform is intended to help clinics optimize their economic model and lower costs.
Traction
The company reports FDA clearance for its Digital Dialysis Clinic (January 2023), first prize in the Israeli 100k MedTech Startup Contest (October 2021), an accepted abstract for poster presentation at ASN Kidney Week 2023, and participation in the European Union's Horizon 2020 research and innovation programme under grant agreement No 827984. It maintains a clinical validation section on its website.
Latest developments
The most recent publicly posted company news is from September 2023: the rebrand from liberDi to iRen Medical, acceptance of an abstract for poster presentation at ASN Kidney Week 2023, and selection as one of 13 companies presenting at Calcalist's 6th Annual Mind the Tech NY in November 2023.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
iRen Medical operates in the peritoneal dialysis and home dialysis segment of the medical device market. It cites data indicating that 88% of dialysis patients are treated with in-clinic hemodialysis and 12% use home dialysis, and positions its platform as a disruption of these traditional treatment pathways.
The company positions its offering as a portable, patient-friendly alternative to both in-clinic hemodialysis and conventional home dialysis, citing automatic catheter connection disinfection technology, freedom of movement during treatment, and integrated remote patient monitoring. It describes the combination of patient device and provider-facing monitoring as a 360-degree platform serving both people with kidney disease and their caregivers.
Technology
The Digital Dialysis Clinic platform centers on the Intelligent Dialysis Assistant (iDA), an electronic automated ambulatory peritoneal dialysis exchange device. Stated features include automatic catheter connection disinfection technology, portability allowing movement during treatment, and remote patient monitoring that lets clinicians follow outcomes while patients dialyze at home or at work.
Go-to-market
The company has pursued regulatory clearance first, obtaining FDA clearance in January 2023, and then rebranded ahead of US marketing efforts. It has used clinical and industry conferences for visibility, including an ASN Kidney Week 2023 poster presentation, MDI EXPO 2023, and Calcalist's Mind the Tech NY 2023, and maintains separate website sections addressing patients and clinicians.
People with kidney disease or kidney failure who are on peritoneal dialysis, along with their families and caregivers, and the dialysis clinics, nephrologists and providers who manage and monitor these patients.
Geography
Headquartered in Misgav, Israel. The company obtained US FDA clearance and cited planned marketing efforts in the United States as a reason for its 2023 rebranding; it has also received European Union Horizon 2020 programme funding and presented at industry and clinical events in Israel and the United States.
History
The company was founded in 2014 as liberDi Ltd., based in Misgav, Israel, and was a portfolio company of The Trendlines Group Ltd. (SGX: 42T; OTCQX: TRNLY). It advanced through the semi-finals and finals of the Israeli 100k MedTech Startup Contest in September and October 2021, winning first prize on 25 October 2021. In January 2023 it announced FDA regulatory clearance for its Digital Dialysis Clinic, and in March 2023 it presented its FDA clearance experience at MDI EXPO 2023 and was featured in an Israel21c article marking World Kidney Day. In September 2023 the company announced it was rebranding from liberDi to iRen-MEDICAL, tying the change to the FDA clearance and to planned US marketing activity. Later in 2023 it had an abstract accepted for poster presentation at ASN Kidney Week (November 1-5, Philadelphia) and was selected as one of 13 companies presenting at Calcalist's 6th Annual Mind the Tech NY (November 5-7).
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 7
launches, deals, and filingsAn abstract on the Intelligent Dialysis Assistant (iDA), an electronic automated ambulatory PD exchange device that is part of the Digital Dialysis Clinic, was accepted for poster presentation at the American Society of Nephrology Kidney Week, held November 1-5, 2023 in Philadelphia.
iRen Medical was one of 13 companies selected to present at Calcalist's 6th Annual Mind the Tech NY conference, held 5-7 November 2023, showcasing its Digital Dialysis Clinic.
The company announced it was renaming itself iRen-MEDICAL, a change it said followed receipt of FDA clearance and preceded its US marketing efforts.
liberDi shared its experience obtaining FDA clearance for its Digital Dialysis Clinic for Home Use with the Israeli medical device community at MDI EXPO 2023.
liberDi Ltd., a portfolio company of The Trendlines Group Ltd. (SGX: 42T; OTCQX: TRNLY), announced it received regulatory clearance from the U.S. Food and Drug Administration for its Digital Dialysis Clinic, which allows patients to perform dialysis at home or at the workplace.
liberDi took first prize in the 100k MedTech Startup Contest, which offered financial prizes of up to ILS 100,000 from Medimor and Poriya plus facilitated access to medical research; more than 70 Israeli medtech startups applied, with liberDi advancing through semi-finals (September 2021) and finals.
The company states its project received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 827984. No amount is disclosed.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Iren Medicaliren-medical.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Iren Medical do?
- Israeli medical device company whose FDA-cleared Digital Dialysis Clinic lets peritoneal dialysis patients treat at home or work.
- Who are Iren Medical's investors?
- Iren Medical's investors include Trendlines Group.
- Where is Iren Medical headquartered?
- Iren Medical is headquartered in Misgav, IL.